Business context and reporting period
Filing identity does not match the request metadata: the supplied filing is for IsoRay, Inc., not Perspective Therapeutics, Inc. It is a Form 10-Q for the quarter ended December 31, 2011, covering the second quarter and first six months of IsoRay’s fiscal year. The financial statements are unaudited.
IsoRay sells Cesium-131 brachytherapy products and the GliaSite Radiation Therapy System. Management described efforts to diversify beyond prostate treatments into brain, lung, and other applications.
Financial results and liquidity
| Metric | Three months ended Dec. 31, 2011 | Six months ended Dec. 31, 2011 |
|---|---|---|
| Product sales | $1.229 million | $2.442 million |
| Gross profit (margin) | $199,000 (16%) | $265,000 (11%) |
| Operating loss | $792,000 | $1.894 million |
| Net loss | $629,000 | $1.731 million |
| Net loss per share | $0.02 | $0.06 |
| Net cash used in operations | Not presented for quarter | $1.014 million |
At December 31, 2011, cash and cash equivalents were $3.381 million; current assets were $5.156 million and current liabilities $761,000. Total liabilities were $1.771 million, including a $318,000 warrant liability and a $693,000 asset retirement obligation. The balance sheet shows no notes payable. Shareholders’ equity was $6.676 million.
For the six months, investing activities used $28,000 and financing activities provided $2.311 million, chiefly from common-stock offerings. Cash increased by $1.269 million. The October offering and December over-allotment generated $2.593 million gross and $2.177 million net proceeds; the company said those proceeds remained unused at December 31.
Material changes versus the prior comparable period
- Six-month sales fell 5% year over year, principally as prostate sales declined 10%. Brain sales rose 184%, lung sales 59%, and GliaSite sales contributed $34,000; non-prostate revenue including GliaSite increased 51%, according to management.
- Six-month gross profit declined 23% and gross margin fell from 13% to 11%, reflecting lower sales and largely fixed production costs. In the December quarter, gross profit rose 55% and margin increased from 10% to 16%, helped by a non-recurring reduction in isotope costs.
- Six-month operating loss widened 26%, as research and development expense rose to $441,000 and sales declined. The prior-year period included a research grant that did not recur.
- Six-month net loss increased from $1.100 million to $1.731 million. A $166,000 noncash gain from revaluing warrant liabilities partially offset the current-period operating loss; the comparable prior-year gain was $420,000.
- Cash from operations used $1.014 million, versus $1.288 million in the prior-year period. The company raised $2.593 million gross in its October/December 2011 stock offering and issued warrants; common shares outstanding increased to 29.316 million from 26.443 million at June 30.
Outlook, commentary, risks, and unusual items
- Management estimated cash and cash equivalents of approximately $3.01 million at February 3, 2012, monthly required cash operating expenditures of about $169,000, and fiscal 2012 capital expenditures below $100,000. It believed available cash would fund operations and capital needs for at least 12 months; this is management’s estimate, not a guarantee.
- Management aimed to reach breakeven by growing existing and new-customer sales, expanding GliaSite, and pursuing additional treatment applications. It cautioned that profitability and revenue growth were uncertain and said additional capital might be needed for studies, staffing, and equipment. Future financing could dilute shareholders or be unavailable on acceptable terms.
- Prostate brachytherapy sales faced competition from treatments with higher reimbursement. Management said prostate sales had declined over several years, while it considered the latest six-month decrease potentially temporary based on a key customer’s purchasing pattern.
- Supply and cost exposure was illustrated by an unscheduled outage at the Russian isotope supplier; a subsequent supplier cost reduction was described as non-recurring.
- A shareholder/licensor disputes the company’s position on a 1% know-how royalty. Prior mediation did not resolve the matter; binding arbitration may be demanded. The filing also notes radioactive-material decommissioning obligations and product-liability exposure, for which the company carries insurance.
- Management reported disclosure controls effective, but said it was continuing remediation of a material weakness and significant deficiency identified in its prior annual report, including recruiting an accounting professional and providing staff training.
Important facts for investors to verify
- Confirm the intended issuer and reporting period: the provided document is IsoRay’s December 31, 2011 Form 10-Q, not a Perspective Therapeutics filing identified as 2011 Q2.
- Check subsequent cash levels, operating cash burn, and whether management’s stated 12-month funding expectation was achieved; the filing gives a February 3 cash estimate of $3.01 million.
- Assess whether non-prostate and GliaSite sales grew enough to offset continued prostate-market weakness, and whether the quarter’s gross-margin improvement persisted after the non-recurring isotope cost reduction.
- Review financing needs and potential dilution, including the issued warrants and the company’s stated possibility of further equity or other financing.
- Follow the royalty dispute, radioactive-material obligations, and progress resolving the previously reported internal-control deficiencies.